Two Days Later: Another Moringa Recall Raises Supply Chain Questions

Recurring Moringa Recalls Highlight Ongoing Supply Chain Concerns

On July 17, the U.S. Food and Drug Administration officially closed its investigation into a multistate Salmonella outbreak linked to MOGO-brand moringa capsules.

The outbreak was not insignificant. According to FDA and the Centers for Disease Control and Prevention, 34 people in 14 states became ill, 11 were hospitalized, and investigators traced the contaminated moringa leaf powder to India. FDA increased screening of imported moringa powder from India and declared the investigation complete.

Two days later, another moringa recall was announced.

This time it involved Zen Principle® Moringa Capsules, recalled after the company’s ingredient supplier informed Relay Peak Research that FDA testing had found Salmonella in the moringa leaf powder used to manufacture the product. No illnesses have been reported, and the company voluntarily recalled the affected lot.

Standing alone, each announcement tells a straightforward story. Together, they tell a different one.

For nearly eight months, we have followed a series of recalls, outbreak investigations, and public health alerts involving moringa products contaminated with Salmonella. What initially appeared to be isolated incidents has gradually revealed a recurring pattern affecting multiple brands and multiple companies.

The timing of the latest recall is particularly noteworthy. FDA had just concluded one investigation, yet another company announced a recall tied to contaminated moringa leaf powder before the ink was dry on the agency’s final update.

That doesn’t necessarily mean these products originated from the same supplier. It doesn’t prove that every moringa product is unsafe. Nor does it suggest FDA’s investigation was incomplete. What it does suggest is that the recurring problem may extend beyond any single manufacturer.

The Zen Principle recall is especially interesting because the product contains little more than moringa leaf powder enclosed in a vegetable capsule. There are few additional ingredients or complex manufacturing steps that could obscure where contamination may have originated. According to the company’s recall notice, the action was prompted after its ingredient supplier reported that FDA testing found Salmonella in the moringa leaf powder itself.

That shifts attention farther upstream in the supply chain.

Modern dietary supplements often travel through an international network of growers, processors, exporters, brokers, ingredient suppliers, contract manufacturers, and retailers before reaching consumers. Every step presents opportunities for contamination—and every recurring recall offers another clue about where preventive controls deserve closer scrutiny.

FDA has responded to each event using the authorities available to it: investigating outbreaks, tracing products, inspecting facilities, coordinating recalls, and warning consumers. Those actions are essential.

But the broader question is no longer about a single recall. It is whether repeated contamination events involving the same botanical ingredient reveal a persistent vulnerability somewhere within the global supply chain.

One recall can be an isolated incident. Several recalls over many months deserve attention. When another moringa recall follows just two days after FDA closes the previous outbreak investigation, it becomes difficult to view the events in isolation.

Sometimes the most important story isn’t the latest recall. It’s the pattern.